{"id":"https://openalex.org/W2020486227","doi":"https://doi.org/10.1038/sj.bjc.6605408","title":"A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate","display_name":"A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate","alternate_titles":[],"publication_year":2010,"publication_date":"2010-01-01","ids":{"openalex":"https://openalex.org/W2020486227","doi":"https://doi.org/10.1038/sj.bjc.6605408","mag":"2020486227","pmid":"https://pubmed.ncbi.nlm.nih.gov/20051961","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2813745"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjc.6605408","doi":"https://doi.org/10.1038/sj.bjc.6605408","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6605408","pdf_url":"https://www.nature.com/articles/6605408.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2020486227"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/6605408.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089714768","display_name":"Marco Falasca","orcid":"https://orcid.org/0000-0002-9801-7235","observed_orcids":["https://orcid.org/0000-0002-9801-7235"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"M Falasca","raw_affiliation_strings":["Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London E1 2AT, UK. m.falasca@qmul.ac.uk","Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London E1 2AT, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London E1 2AT, UK. m.falasca@qmul.ac.uk","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London E1 2AT, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041363617","display_name":"Daniela Chiozzotto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D Chiozzotto","raw_affiliation_strings":["Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London, E1 2AT, UK","Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London, E1 2AT, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055088925","display_name":"H. Yasmin Godage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51601045","display_name":"University of Bath","ror":"https://ror.org/002h8g185","country_code":"GB","type":"education","lineage":["https://openalex.org/I51601045"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"H Y Godage","raw_affiliation_strings":["Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK","institution_ids":["https://openalex.org/I51601045"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058567743","display_name":"Marco Mazzoletti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"M Mazzoletti","raw_affiliation_strings":["Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","institution_ids":["https://openalex.org/I19630809"]},{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023315844","display_name":"Andrew M. Riley","orcid":"https://orcid.org/0000-0001-9003-3540","observed_orcids":["https://orcid.org/0000-0001-9003-3540"]},"institutions":[{"id":"https://openalex.org/I51601045","display_name":"University of Bath","ror":"https://ror.org/002h8g185","country_code":"GB","type":"education","lineage":["https://openalex.org/I51601045"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A M Riley","raw_affiliation_strings":["Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK","institution_ids":["https://openalex.org/I51601045"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027811827","display_name":"Sara Previdi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"S Previdi","raw_affiliation_strings":["Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","institution_ids":["https://openalex.org/I19630809"]},{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113898464","display_name":"Barry V. L. Potter","orcid":"https://orcid.org/0000-0003-3255-9135","observed_orcids":["https://orcid.org/0000-0003-3255-9135"]},"institutions":[{"id":"https://openalex.org/I51601045","display_name":"University of Bath","ror":"https://ror.org/002h8g185","country_code":"GB","type":"education","lineage":["https://openalex.org/I51601045"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B V L Potter","raw_affiliation_strings":["Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy and Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK","institution_ids":["https://openalex.org/I51601045"]},{"raw_affiliation_string":"Department of Pharmacy & Pharmacology, Wolfson Laboratory of Medicinal Chemistry, University of Bath, Claverton Down, Bath, UK","institution_ids":["https://openalex.org/I51601045"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091714925","display_name":"Massimo Broggini","orcid":"https://orcid.org/0000-0002-8138-9358","observed_orcids":["https://orcid.org/0000-0002-8138-9358"]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"M Broggini","raw_affiliation_strings":["Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, 20156, Italy","institution_ids":["https://openalex.org/I19630809"]},{"raw_affiliation_string":"Department of Oncology, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche, \u2018Mario Negri\u2019, Milan, Italy","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055003493","display_name":"Tania Maffucci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T Maffucci","raw_affiliation_strings":["Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London, E1 2AT, UK","Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London, E1 2AT, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London, UK","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5089714768"],"corresponding_institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":3.2274,"has_fulltext":true,"cited_by_count":59,"citation_normalized_percentile":{"value":0.93245457,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"102","issue":"1","first_page":"104","last_page":"114"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.9079999923706055},{"id":"https://openalex.org/keywords/pdk1-inhibition","display_name":"PDK1 inhibition","score":0.8690000176429749},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.9779999852180481},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.8840000033378601},{"id":"https://openalex.org/keywords/structure-activity-modification","display_name":"structure-activity modification","score":0.6150000095367432},{"id":"https://openalex.org/keywords/antitumour-activity","display_name":"antitumour activity","score":0.6800000071525574},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6880000233650208},{"id":"https://openalex.org/keywords/kinase-profiling","display_name":"kinase profiling","score":0.49799999594688416}],"concepts":[{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.8115411400794983},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7836230397224426},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5441038608551025},{"id":"https://openalex.org/C2777427919","wikidata":"https://www.wikidata.org/wiki/Q407997","display_name":"Inositol","level":3,"score":0.5422834157943726},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.5100546479225159},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48143360018730164},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.4386175274848938},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.42909619212150574},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.42597922682762146},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4147481322288513},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4091966152191162},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3950234055519104},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.38884487748146057},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3637100160121918},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.33419060707092285},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19222936034202576},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1263677179813385},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000230","descriptor_name":"Adenocarcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D000230","descriptor_name":"Adenocarcinoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004789","descriptor_name":"Enzyme Activation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007295","descriptor_name":"Inositol Phosphates","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D007295","descriptor_name":"Inositol Phosphates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007295","descriptor_name":"Inositol Phosphates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007295","descriptor_name":"Inositol Phosphates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":"Q000637","qualifier_name":"transplantation","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D047908","descriptor_name":"Intracellular Signaling Peptides and Proteins","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1038/sj.bjc.6605408","doi":"https://doi.org/10.1038/sj.bjc.6605408","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6605408","pdf_url":"https://www.nature.com/articles/6605408.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:1909042","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2813745","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:20051961","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20051961","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2813745","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2813745/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmh:oai:ora.ox.ac.uk:uuid:62b71ca4-ccfb-4ca3-abb0-f5440a02804e","doi":null,"is_oa":true,"landing_page_url":"https://ora.ox.ac.uk/objects/uuid:62b71ca4-ccfb-4ca3-abb0-f5440a02804e/files/m1324d2949c5b59010646447f6f60226c","pdf_url":null,"source":{"id":"https://openalex.org/S4306402636","display_name":"Oxford University Research Archive (ORA) (University of Oxford)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I40120149","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/I40120149"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Symplectic Elements at Oxford","raw_type":"Journal article"},{"id":"pmh:oai:espace.curtin.edu.au:20.500.11937/23657","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/20.500.11937/23657","pdf_url":null,"source":{"id":"https://openalex.org/S4306401790","display_name":"eSpace (Curtin University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I205640436","host_organization_name":"Curtin University","host_organization_lineage":["https://openalex.org/I205640436"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1038/sj.bjc.6605408","doi":"https://doi.org/10.1038/sj.bjc.6605408","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6605408","pdf_url":"https://www.nature.com/articles/6605408.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1146265072","display_name":"Chemical biology, inositol polyphosphates and cell signalling.","funder_award_id":"082837/Z/07/Z","funder_id":"https://openalex.org/F4320311904","funder_display_name":"Wellcome Trust"},{"id":"https://openalex.org/G6189842978","display_name":"Role of phosphoinositide 3-kinase/plc pathway in angiogenesis","funder_award_id":"PG/04/033/16906","funder_id":"https://openalex.org/F4320319992","funder_display_name":"British Heart Foundation"}],"funders":[{"id":"https://openalex.org/F4320311904","display_name":"Wellcome Trust","ror":"https://ror.org/029chgv08"},{"id":"https://openalex.org/F4320319992","display_name":"British Heart Foundation","ror":"https://ror.org/02wdwnk04"},{"id":"https://openalex.org/F4320320300","display_name":"European Commission","ror":"https://ror.org/00k4n6c32"},{"id":"https://openalex.org/F4320324143","display_name":"Fondazione Italiana per la Ricerca sul Cancro","ror":"https://ror.org/02g2x7380"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2020486227.pdf","grobid_xml":"https://content.openalex.org/works/W2020486227.grobid-xml"},"referenced_works_count":57,"referenced_works":["https://openalex.org/W1594020010","https://openalex.org/W1779463793","https://openalex.org/W1797430954","https://openalex.org/W1831026143","https://openalex.org/W1834339553","https://openalex.org/W1968109047","https://openalex.org/W1981711832","https://openalex.org/W1984562250","https://openalex.org/W1984621921","https://openalex.org/W1984879511","https://openalex.org/W1997611649","https://openalex.org/W2006579698","https://openalex.org/W2008543595","https://openalex.org/W2011610189","https://openalex.org/W2014031706","https://openalex.org/W2014096417","https://openalex.org/W2018023891","https://openalex.org/W2020891498","https://openalex.org/W2021012077","https://openalex.org/W2025391287","https://openalex.org/W2027731629","https://openalex.org/W2047255238","https://openalex.org/W2047392226","https://openalex.org/W2058720172","https://openalex.org/W2069232844","https://openalex.org/W2080100938","https://openalex.org/W2083592023","https://openalex.org/W2087861588","https://openalex.org/W2095304369","https://openalex.org/W2095960945","https://openalex.org/W2096806896","https://openalex.org/W2097501957","https://openalex.org/W2102014488","https://openalex.org/W2112842133","https://openalex.org/W2113925725","https://openalex.org/W2117263216","https://openalex.org/W2126404692","https://openalex.org/W2126783165","https://openalex.org/W2129926488","https://openalex.org/W2131739722","https://openalex.org/W2134138119","https://openalex.org/W2141425188","https://openalex.org/W2141820814","https://openalex.org/W2144323242","https://openalex.org/W2148053550","https://openalex.org/W2150225976","https://openalex.org/W2150504453","https://openalex.org/W2151791302","https://openalex.org/W2157983986","https://openalex.org/W2158753973","https://openalex.org/W2160550349","https://openalex.org/W2161221839","https://openalex.org/W2163535846","https://openalex.org/W2164139183","https://openalex.org/W2261566286","https://openalex.org/W2388163742","https://openalex.org/W4238567307"],"related_works":["https://openalex.org/W1984562250","https://openalex.org/W2073749629","https://openalex.org/W1779463793","https://openalex.org/W2161221839","https://openalex.org/W2064538026","https://openalex.org/W1981811774","https://openalex.org/W2914954344","https://openalex.org/W3091087244","https://openalex.org/W4245509295","https://openalex.org/W2086281394"],"abstract_inverted_index":{"BACKGROUND:":[0],"Owing":[1],"to":[2,44,110,165,187],"its":[3,42],"role":[4],"in":[5,32,86,112,115,124,142,145,156,177],"cancer,":[6],"the":[7,23,50,129,146,151,171,192],"phosphoinositide":[8],"3-kinase":[9],"(PI3K)/Akt":[10],"pathway":[11,194],"is":[12,104,163],"an":[13],"attractive":[14],"target":[15,173],"for":[16],"therapeutic":[17],"intervention.":[18],"We":[19],"previously":[20],"reported":[21],"that":[22,167],"inhibition":[24],"of":[25,49,78,131,154,174,191],"Akt":[26,67,155],"by":[27,58,71,93],"inositol":[28],"1,3,4,5,6-pentakisphosphate":[29,102],"(InsP(5))":[30],"results":[31],"anti-tumour":[33],"properties.":[34],"To":[35],"further":[36],"develop":[37,188],"this":[38],"compound":[39],"we":[40],"modified":[41],"structure":[43],"obtain":[45],"more":[46],"potent":[47],"inhibitors":[48,190],"PI3K/Akt":[51,193],"pathway.":[52],"METHODS:":[53],"Cell":[54],"proliferation/survival":[55],"was":[56,69,80,91],"determined":[57,70,92],"cell":[59,157],"counting,":[60],"sulphorhodamine":[61],"or":[62],"acridine":[63],"orange/ethidium":[64],"bromide":[65],"assay;":[66],"activation":[68],"western":[72],"blot":[73],"analysis.":[74],"In":[75],"vivo":[76],"effect":[77,130],"compounds":[79,186],"tested":[81],"on":[82,89],"PC3":[83],"xenografts,":[84],"whereas":[85],"vitro":[87,113,143],"activity":[88,121],"kinases":[90],"SelectScreen":[94],"Kinase":[95],"Profiling":[96],"Service.":[97],"RESULTS:":[98],"The":[99],"derivative":[100],"2-O-benzyl-myo-inositol":[101],"(2-O-Bn-InsP(5))":[103],"active":[105],"towards":[106],"cancer":[107],"types":[108],"resistant":[109],"InsP(5)":[111,123,180],"and":[114,127,150,159,181,200],"vivo.":[116],"2-O-Bn-InsP(5)":[117,134,168,182],"possesses":[118],"higher":[119],"pro-apoptotic":[120],"than":[122],"sensitive":[125],"cells":[126],"enhances":[128],"anti-cancer":[132,203],"compounds.":[133],"specifically":[135],"inhibits":[136,170],"3-phosphoinositide-dependent":[137],"protein":[138],"kinase":[139],"1":[140],"(PDK1)":[141],"(IC(50)":[144],"low":[147],"nanomolar":[148],"range)":[149],"PDK1-dependent":[152],"phosphorylation":[153],"lines":[158],"excised":[160],"tumours.":[161],"It":[162],"interesting":[164],"note":[166],"also":[169],"mammalian":[172],"rapamycin":[175],"(mTOR)":[176],"vitro.":[178],"CONCLUSIONS:":[179],"may":[183],"represent":[184],"lead":[185],"novel":[189,201],"(including":[195],"potential":[196,202],"dual":[197],"PDK1/mTOR":[198],"inhibitors)":[199],"drugs.":[204]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2020486227","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":14}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
